Abbott Laboratories (NYSE:ABT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Abbott Laboratories (NYSE:ABT) have received a consensus recommendation of “Moderate Buy” from the twenty-eight brokerages that are covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and three have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $118.88.

A number of equities analysts recently commented on the stock. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a research note on Thursday, August 13th. JPMorgan Chase & Co. lifted their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Wells Fargo & Company upped their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Barclays assumed coverage on Abbott Laboratories in a report on Wednesday. They issued an “overweight” rating and a $120.00 price objective on the stock. Finally, Bank of America cut their target price on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th.

Abbott Laboratories Stock Up 0.5%

Shares of NYSE:ABT opened at $98.70 on Thursday. The firm’s 50 day moving average price is $106.52 and its 200 day moving average price is $98.39. The stock has a market cap of $170.79 billion, a price-to-earnings ratio of 31.94, a price-to-earnings-growth ratio of 1.82 and a beta of 0.59. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $135.13. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the previous year, the business posted $1.26 EPS. The firm’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. BlackRock Inc. boosted its stake in Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after acquiring an additional 6,769,518 shares in the last quarter. State Street Corp lifted its holdings in shares of Abbott Laboratories by 1.7% in the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares during the last quarter. Capital International Investors boosted its position in shares of Abbott Laboratories by 2.6% in the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after purchasing an additional 1,614,706 shares during the period. J. Stern & Co. LLP grew its stake in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after buying an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors grew its stake in Abbott Laboratories by 1.0% during the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after buying an additional 400,400 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays began coverage with an Overweight rating and a $120 price target, implying substantial upside from the recent trading level. The call reflects a more favorable view of Abbott and the broader medical-technology sector. Stryker, Abbott among overweight ideas as Barclays turns bullish on MedTech
• Positive Sentiment: Additional analyst coverage reportedly started on a bullish note, potentially improving sentiment toward ABT following its recent weakness. This Abbott Analyst Begins Coverage On A Bullish Note
• Positive Sentiment: Abbott launched Ensure Max Protein 3-in-1 Muscle Support, a powder combining 30 grams of protein, 5 grams of creatine and 3 grams of calcium HMB. The product expands Abbott’s nutrition portfolio and targets growing mainstream interest in muscle health and fitness. Abbott introduces Ensure Max Protein 3-in-1 Muscle Support
• Neutral Sentiment: Investor-focused coverage highlights Abbott’s 411 consecutive quarterly dividend payments since 1924. The consistency may appeal to income-oriented investors, although the company is not currently demonstrating rapid growth. Is Abbott Laboratories a Dividend Bargain After Its 2026 Selloff?
• Negative Sentiment: ABT recently declined even as the broader market advanced, underscoring lingering concerns about valuation, growth momentum or sector-specific pressures. The stock’s 2026 selloff has increased its dividend appeal but also signals that investors remain cautious. Abbott Stock Drops Despite Market Gains

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.